Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949286 | 0.81 | HPGDS (0.49) | GPR119HPGDSTP53MEN1KMT2A | |
| SCHEMBL947723 | 0.78 | GPR119 (0.49) | GPR119HPGDSTP53KMT2AKDM4E | |
| SCHEMBL949430 | 0.77 | GPR119 (0.50) | GPR119HPGDSTP53MEN1KMT2A | |
| SCHEMBL948735 | 0.76 | GPR119 (0.49) | GPR119MEN1KMT2AKDM4EMAPT | |
| SCHEMBL7868718 | 0.75 | PIK3CA (0.46) | GPR119HPGDSKDM4E | |
| SCHEMBL7545748 | 0.75 | GPR119 (0.45) | GPR119HPGDSTP53MEN1KMT2A | |
| SCHEMBL7547603 | 0.75 | POLB (0.48) | GPR119HPGDSTP53MEN1KMT2A | |
| SCHEMBL947924 | 0.75 | GPR119 (0.47) | GPR119HPGDSTP53MEN1KMT2A | |
| SCHEMBL7544334 | 0.74 | HPGDS (0.52) | GPR119HPGDSTP53MEN1KMT2A | |
| SCHEMBL7863410 | 0.74 | PIK3CA (0.46) | GPR119HPGDSTP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1564213-A1 | IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | HRH4, F2, HRH2 | GPR119 1327/4885HPGDS 142/4885TP53 4661/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | GPR119 1118/4885HPGDS 74/4885TP53 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.